India launches 1st indigenous CRISPR-based gene therapy for Sickle Cell Disease
New Delhi, Nov 19 (IANS) Setting a new milestone in Atmanirbhar Bharat, the government on Wednesday launched an indigenous CRISPR-based gene therapy for Sickle Cell Disease, which particularly affects India's tribal population.
The world-class, low-cost gene editing solution named "BIRSA 101", in honour of Bhagwan Birsa Munda, remembered as a great tribal freedom fighter, was launched by Union Minister of State (Independent Charge) for Science and Technology Dr.
The technology works like a “precise genetic surgery”, capable not only of curing Sickle Cell Disease but also transforming treatment pathways for several hereditary disorders, the Minister explained.
Sickle Cell Disease is a chronic, single-gene disorder that causes a debilitating systemic syndrome characterised by chronic anaemia, acute painful episodes, organ infarction, and chronic organ damage, significantly reducing life expectancy.
The genetic blood disorder affects the entire life of the patient, as it leads to various severe health complications.
"India has formally begun its decisive journey towards becoming a Sickle Cell Disease–free nation, marking a historic turning point in the country’s public health and genomic medicine landscape,” Singh said.
“With the development and transfer of India’s first indigenous CRISPR-based gene therapy, the nation has taken a major step toward fulfilling Prime Minister Narendra Modi’s vision of a Sickle Cell–Free India by 2047, while simultaneously advancing the goal of Atmanirbhar Bharat in frontline medical technologies,” he added.